According to the study “Small-Cell Lung Cancer - Pipeline Review, H1 2018”,
the market for small cell lung cancer treatment is geographically spread across
Americas, Europe, and Asia Pacific excluding Japan, Japan and Middle East &
Africa. America accounts for better treatment options because it is a highly
developed region with more healthcare facilities and more population are aware
about small cell lung cancer. Asia Pacific and Europe countries are expecting a
remarkable growth in the small cell lung cancer treatment market. According to
World Health Organization (WHO) reports, more than 10 million people are
affected with cancer which is one of the leading causes of death. The leading
cancer type is lung cancer that accounts for the majority of the deaths. The leading key players of small-cell lung cancer
market are AbbVie Inc, Advenchen Laboratories LLC, Aeglea
BioTherapeutics Inc, Amgen Inc, Andarix Pharmaceuticals Inc, Aposense Ltd,
Aprea AB, Ascentage Pharma Group Corp Ltd, Astellas Pharma Inc and others.
Cancer occurs due to cell transformation where normal cells grow
and multiply without control. The common cause of mortality and morbidity worldwide
is lung cancer that is caused majorly due to smoking. Lung cancer is
categorized into two types such as non-small cell lung cancer and small cell
lung cancer. Small cell lung cancer is caused due to smoking tobacco, or second
hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or
radon. The symptoms associated with lung cancer are chest pain, incurable
cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss,
shortness of breath, and wheezing. Small cell lung cancer cannot be diagnosed
at an early stage and can be diagnosed only at the late stage of disease
progression leading to more number of deaths. Small cell lung cancer is recurrent
in nature, spreads quickly and is difficult to cure at a go. This cancer usually
starts in the breathing tubes (bronchi) in the center of the chest as tumors and
often spread rapidly to the other parts of the human body, including brain,
liver, and bone.
The major risk factors for small cell lung
cancer are modernization,
smoking, increased alcohol consumption, unhealthy food, air pollution, chronic
infections, family history of lung cancer, HIV, exposure to triggers and
carcinogens such as radon gas, exposure to radioactive materials, air pollution
and no physical activity are indirectly driving the global small cell lung
cancer market. All the emerging economies are providing awareness among the
people about the small cell lung cancer. Various available treatments for small
cell lung cancer are surgery, radiation therapy and chemotherapy. Surgery is
performed to remove malignant tumor and lymph node in lungs. Chemotherapy
treatment is given at an early stage of small cell lung cancer. Radiation
therapy is given to shrink tumor cells, to relieve symptoms such as bleeding,
cough, trouble swallowing and shortness of breath. Three-dimensional conformal
radiation therapy (3D-CRT) and Intensity modulated radiation therapy (IMRT) are
the two types of radiation methods used in small cell lung cancer treatment.
The pipeline review on small cell lung cancer market provides
a comprehensive analysis on various key players, targeted therapeutics under
development, drug target, mechanism of action (MoA), route of administration
(RoA), molecule type, descriptive pharmacological action of the therapeutics,
complete research and development history, summary of all the dormant and
discontinued projects, latest news reports,
press releases reports, thoughtful insights, facts, historical
data, statistically supported industry-validated market data, a suitable set of
assumptions and methodologies, geography, applications, market segments, market
dynamics, market size, supply, demand, current trends/issues/challenges,
competition, technology, value chain, in-depth analysis on new and available
drugs, macro-economic indicators, governing factors along with market
attractiveness, latest industry trends and developments. Global small cell lung
cancer therapeutics market will witness an advance higher growth rate as
compared to previous years due to increasing in instances of smoking, rising
cases of lung infections, and increasing rate of lung cancers. Therefore, there
will be an increasing demand for small cell lung cancer drugs over the next few
years.
To know more, click on the link below:
Related
Reports:-
Contact
Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
